Accessibility Archives - Page 3 of 4

Home
/
Projects
/

Accessibility

Accessibility refers to equitable delivery aimed at all who could benefit from a new TB vaccine for adults and adolescents. This includes defined implementation strategies, having delivery systems and sustainable financing strategies in place. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

Accelerating access to novel TB vaccines

2024-2027

Hypothetical vaccines

Development of global early-stage, needs-based demand forecast for novel TB vaccines as input for the TB Vx Accelerator Finance and Access Working Group; identification of access barriers and problem solving for resultion

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report

2024

A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.

Formative work to understand factors affecting future TB vaccines acceptance and readiness

2023-2027

Hypothetical vaccines

This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance

TB vaccine advocacy roadmap

2021

The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/

Innovative Financing for TB vaccine R&D

2023

T20 policy brief

Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review

2023

This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).

Country and target population prioritization

2023-2025

Hypothetical vaccines

Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

2023

Hypothetical vaccines

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines

2022

BCG revaccination, M72/AS01e

Our study provides crucial information for implementing novel TB vaccines in specific target groups and on country specific acceptability and feasibility. Key groups for vaccine implementation in these settings were identified, and should be included in clinical trials and implementation planning.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024

BCG revaccination, Hypothetical vaccines, M72/AS01e

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.